<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451372</url>
  </required_header>
  <id_info>
    <org_study_id>SW01</org_study_id>
    <nct_id>NCT01451372</nct_id>
  </id_info>
  <brief_title>Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study</brief_title>
  <official_title>Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to document the routine practice in continuous glucose monitoring
      (CGM) in patients treated with sensor-augmented pump therapy and to assess clinical outcome
      (HbA1c) before the start of the sensor use to the end of the follow-up period. Moreover, data
      on treatment satisfaction, and fear of hypoglycemia, cost of the therapy, side effects and
      treatment interruption will be collected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most advanced technologies for the treatment of type 1 diabetes mellitus (T1DM) include
      insulin pumps for continuous subcutaneous insulin infusion (CSII) and glucose sensors
      allowing continuous glucose monitoring(CGM). Randomized controlled trials have shown that
      access to CGM can improve control in poorly-controlled patients regardless of insulin
      treatment therapy via reduced hyper- and hypoglycaemic excursions and improved mean HbA1c
      value.

      The Medtronic personal CGM device is composed of a glucose sensor linked to a MiniLink
      REAL-Time Transmitter, which transmits data from the glucose sensor to the insulin pump. The
      integration of these two technologies (CSII and personal CGM) into one system is called
      sensor-augmented pump therapy (SAP).The devices are CE-marked and routinely used in clinical
      practice in the Swedish market.

      Based on the clinical evidences provided, the Swedish Dental and Pharmaceutical Benefits
      Agency (TLV) concluded that the personal CGM when used in combination to a Medtronic insulin
      pump as SAP should be included in the Swedish reimbursement system. However the decision was
      upon specific patient indications:

      Patients with two or more severe hypoglycemias/year that require help from another person or
      Patients with HbA1c of at least 9%, in cases where optimized insulin therapy has not been
      effective or Children taking at least 10 medically required plasma glucose tests
      (fingersticks) per 24 hours and that certain follow-up information has to be complemented and
      submitted to TLV before March 1st, 2012.

      TLV requires follow-up information on T1 diabetes patients using SAP in Swedish clinical
      practice and based on the following outcome parameters:

      HbA1c-level of the patients Quality of life with use of CGM Side effects and therapy
      interruptions. Use and costs of the therapy Frequency of hypoglycemia Therefore, this project
      will observe the routine practice of personal CGM utilization in combination to Medtronic
      insulin pumps in T1DM patients in Sweden in approximately 15 investigational centers.

      The aim of this project is to reflect the daily practice in personal CGM therapy (sensor and
      MiniLink REAL-Time Transmitter) usage in diabetes patients treated with Medtronic insulin
      pumps in Sweden. Data on the HbA1c value before and up to six months use of personal CGM will
      be collected and information on the outcomes requested by TLV will be included in the study.
      The patient reported outcomes will be supplemented with patient preference data and will be
      estimated with a willingness-to-pay (WTP) approach.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Daily Usage of Blood Glucose Test (BG Testing)</measure>
    <time_frame>24 months</time_frame>
    <description>Daily usage of blood glucose test 0-24 months after CGM usage. This information is collected in a journal questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Sensor Usage Per Month</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of sensor usage per month during the study. This information is collected in a journal questionnaire</description>
  </secondary_outcome>
  <enrollment type="Actual">69</enrollment>
  <condition>Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Population will be selected from Primary Care Clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (and/or legal representative) has signed Patient Informed Consent(PIC) AND

          -  Patient (0-69 years) was diagnosed with Type 1 DM and has been on insulin pump therapy
             (without any additional insulin injection) for at least 3 months prior to signature of
             the PIC AND

          -  HbA1c ≥ 7 %) or

          -  has experienced at least 2 severe hypoglycemic events in the last 12 months or

          -  is performing on average more than 10 SMBG per day AND The patient has used, or is
             using or will start using continuous glucose monitoring as part of the CSII therapy
             for at least 70% of the time for a minimum of 3 months.

        Exclusion Criteria:

          -  Participation in any other clinical trial - currently and/or in the last 3 months
             prior signature of informed consent and/or during the retrospective period of data
             collection.

          -  Unwillingness to perform at least 4 BG tests per day

          -  Unwillingness to maintain contact with HCP

          -  For children: no reliable contact person

          -  PREGNANT woman and wish of pregnancy

          -  Vision and hearing impairment not allowing pump use

          -  Any disease or drug treatment that can interfere with the outcome of sensor usage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Örtqvist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ALB, Karolinska Universitetssjukhuset Solna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medtronic AB</name>
      <address>
        <city>Stockholm</city>
        <state>Kista</state>
        <zip>164 21</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <results_first_submitted>March 22, 2018</results_first_submitted>
  <results_first_submitted_qc>October 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>October 18, 2018</last_update_submitted>
  <last_update_submitted_qc>October 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>CGM</keyword>
  <keyword>CSII</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Type 1 Diabetes Subjects Using CGM</title>
          <description>Type 1 Diabetes Subjects using CGM in Sweden</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Type 1 Diabetes Subjects Using CGM</title>
          <description>Type 1 Diabetes Subjects using CGM in Sweden</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age, Continuous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="3" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daily Usage of Blood Glucose Test (BG Testing)</title>
        <description>Daily usage of blood glucose test 0-24 months after CGM usage. This information is collected in a journal questionnaire</description>
        <time_frame>24 months</time_frame>
        <population>journal questionnaires about blood glucose testing were collected from 65 out of 69 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes Subjects Using CGM</title>
            <description>Type 1 Diabetes Subjects using CGM in Sweden</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Usage of Blood Glucose Test (BG Testing)</title>
          <description>Daily usage of blood glucose test 0-24 months after CGM usage. This information is collected in a journal questionnaire</description>
          <population>journal questionnaires about blood glucose testing were collected from 65 out of 69 subjects</population>
          <units>number of blood glucose test per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Sensor Usage Per Month</title>
        <description>Frequency of sensor usage per month during the study. This information is collected in a journal questionnaire</description>
        <time_frame>24 months</time_frame>
        <population>Journal questionnaires about sensor usage were collected from 61 out of 69 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Type 1 Diabetes Subjects Using CGM</title>
            <description>Type 1 Diabetes Subjects using CGM in Sweden</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Sensor Usage Per Month</title>
          <description>Frequency of sensor usage per month during the study. This information is collected in a journal questionnaire</description>
          <population>Journal questionnaires about sensor usage were collected from 61 out of 69 subjects</population>
          <units>number of sensor used per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Type 1 Diabetes Subjects Using CGM</title>
          <description>Type 1 Diabetes Subjects using CGM in Sweden</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suiying Huang, Statistician</name_or_title>
      <organization>Medtronic Minimed</organization>
      <phone>8184763319</phone>
      <email>suiying.huang@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

